Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.81 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.81 |
| ▸ | TUBB | P07437 | 5/20 | 0.81 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.81 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.81 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.81 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.81 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.81 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.81 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.81 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.81 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.81 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.81 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.81 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.81 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073426 | 0.93 | CYP3A4 (0.70) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL682243 | 0.93 | CYP3A4 (0.70) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL12145856 | 0.93 | CYP3A4 (0.82) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| Noscapine SCHEMBL12481369 | 0.90 | CYP3A4 (1.00) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| Noscapine SCHEMBL2494164 | 0.90 | CYP3A4 (1.00) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| Noscapine SCHEMBL14400084 | 0.90 | CYP3A4 (1.00) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| Noscapine SCHEMBL10307295 | 0.90 | CYP3A4 (1.00) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| Noscapine SCHEMBL7862895 | 0.90 | CYP3A4 (1.00) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| Noscapine SCHEMBL4559 | 0.90 | CYP3A4 (1.00) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B | |
| Noscapine SCHEMBL29365828 | 0.90 | CYP3A4 (1.00) | CYP3A4TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889705-B2 | Noscapine analogs and their use in treating cancers | EMORY UNIVERSITY (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130224310-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS | EMORY UNIVERSITY (US) | 2013-08-29 | — | — | US | disclosed |
| US-8426398-B2 | Conjugates of noscapine and folic acid and their use in treating cancer | EMORY UNIVERSITY (US) | 2013-04-23 | — | — | US | disclosed |
| US-20130045203-A1 | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP | EMORY UNIVERSITY (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120053199-A1 | NOSCAPINE AND ANALOGS AND METHODS RELATED THERETO | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2012-03-01 | — | — | US | disclosed |
| US-20110286919-A1 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | EMORY UNIVERSITY (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | EMORY UNIVERSITY (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109237-A2 | USES OF NOSCAPINE AND DERIVATIVES IN SUBJECTS DIAGNOSED WITH FAP | EMORY UNIVERSITY (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224310-A1 | NOSCAPINE ANALOGS AND THEIR USE IN TREATING CANCERS | TUBA1C, TUBB1, TUBB3 | CYP3A4 1238/4885TUBB4A 9/4885TUBB 4/4885 |
| US-20120053199-A1 | NOSCAPINE AND ANALOGS AND METHODS RELATED THERETO | NOS2, NOS1, NOS3 | CYP3A4 1678/4885TUBB4A 3007/4885TUBB 3641/4885 |
| US-20110286919-A1 | CONJUGATES OF NOSCAPINE AND FOLIC ACID AND THEIR USE IN TREATING CANCER | FOLR1, FOLR2, DHFR | CYP3A4 550/4885TUBB4A 2968/4885TUBB 3211/4885 |
| US-20110274651-A1 | Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition | NOS1, NOS2, TBCA | CYP3A4 2578/4885TUBB4A 13/4885TUBB 8/4885 |
| US-20130045203-A1 | Uses of Noscapine and Derivatives in Subjects Diagnosed with FAP | APC, FAP, NTPCR | CYP3A4 1024/4885TUBB4A 2727/4885TUBB 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.